Kristofer Prepelica, PhD 11/10/25 Kristofer Prepelica, PhD 11/10/25

2026 Summer Internship Program

Read More

Kristofer Prepelica, PhD 11/6/25 Kristofer Prepelica, PhD 11/6/25

PCCTC Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum

Read More

Kristofer Prepelica, PhD 11/3/25 Kristofer Prepelica, PhD 11/3/25

Prespecified Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study

Read More

Kristofer Prepelica, PhD 10/24/25 Kristofer Prepelica, PhD 10/24/25

The PCCTC’s Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) Activated

Read More

Kristofer Prepelica, PhD 10/14/25 Kristofer Prepelica, PhD 10/14/25

PCCTC-managed Phase 1 Study of K36’s Novel NSD2 Inhibitor KTX-2001 Activated

Read More

Kristofer Prepelica, PhD 6/30/25 Kristofer Prepelica, PhD 6/30/25

Results from Cohorts 4 and 5 of the Phase 2 KEYNOTE-199 Study Published

Read More

Kristofer Prepelica, PhD 6/26/25 Kristofer Prepelica, PhD 6/26/25

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPIs: A Multinational Real-World Analysis of the IRONMAN Registry

Read More

Kristofer Prepelica, PhD 5/22/25 Kristofer Prepelica, PhD 5/22/25

The PCCTC at ASCO 2025

Read More

Dr. Howard I. Scher Honored with Richard D. Williams, MD Prostate Cancer Research Excellence Award

Kristofer Prepelica, PhD 4/25/25 Kristofer Prepelica, PhD 4/25/25

Dr. Howard I. Scher Honored with Richard D. Williams, MD Prostate Cancer Research Excellence Award

Read More

Kristofer Prepelica, PhD 3/17/25 Kristofer Prepelica, PhD 3/17/25

The PCCTC at SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC

Read More

Kristofer Prepelica, PhD 2/7/25 Kristofer Prepelica, PhD 2/7/25

The PCCTC at ASCO GU 2025

Read More

Kristofer Prepelica, PhD 12/24/24 Kristofer Prepelica, PhD 12/24/24

Summer Internships Announced

Read More

Kristofer Prepelica, PhD 9/24/24 Kristofer Prepelica, PhD 9/24/24

CDMRP Features PCCTC-Managed PROMISE Registry

Read More

Kristofer Prepelica, PhD 9/17/24 Kristofer Prepelica, PhD 9/17/24

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC

Read More

Kristofer Prepelica, PhD 9/13/24 Kristofer Prepelica, PhD 9/13/24

Results Published from PCCTC Study of Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy

Read More

Kristofer Prepelica, PhD 9/4/24 Kristofer Prepelica, PhD 9/4/24

6th Annual NYC Prostate Cancer Summit to Feature PCCTC Investigators

Read More

Kristofer Prepelica, PhD 8/26/24 Kristofer Prepelica, PhD 8/26/24

The Prostate Cancer Clinical Trials Consortium (PCCTC) Receives Gift from Friends and Family Against Prostate Cancer

Read More

Kristofer Prepelica, PhD 8/8/24 Kristofer Prepelica, PhD 8/8/24

Results from the PCCTC-managed Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line mCRPC with DNA Repair Defects (BRCAAway) Study Published in Clinical Cancer Research

Read More

Kristofer Prepelica, PhD 7/9/24 Kristofer Prepelica, PhD 7/9/24

American Cancer Society, Trial Library, and the PCCTC Collaborate to Support Recruitment of Black Patients for Clinical Trials

The American Cancer Society announced a new collaboration with Trial Library, Inc., and the PCCTC to support a national initiative to accelerate the recruitment of Black patients to prostate cancer clinical trials.

Read More

Kristofer Prepelica, PhD 4/21/24 Kristofer Prepelica, PhD 4/21/24

PCCTC Investigator Dr. Rana McKay Wins the 2024 Christopher G. Wood Rising Star Award at IKCS Europe

Dr McKay won the 2024 Christopher G. Wood Rising Star Award at IKCS Europe, which took place in Sitges, Spain between April 18th and 20th, 2024.

Read More